Supplements and Glaucoma: What Can Actually Help Lower IOP

Glaucoma is the second leading cause of irreversible blindness worldwide, affecting over 80 million people. It is characterized by progressive damage to the optic nerve, most commonly (though not always) associated with elevated intraocular pressure (IOP). Treatment that effectively lowers IOP slows or halts optic nerve damage — and this is accomplished through prescription eye drops, laser procedures, or surgery. The role of supplements in glaucoma management is at best adjunctive and must be understood with that hierarchy firmly in place.

The IOP-centric model of glaucoma

Most glaucoma occurs in the open-angle form: the drainage angle of the eye is anatomically open but functionally insufficient, causing IOP to rise above the range the optic nerve can tolerate. Standard first-line treatment is prostaglandin analog eye drops (latanoprost, travoprost, bimatoprost), which increase uveoscleral outflow and typically reduce IOP by 25–35%.

Normal-tension glaucoma (NTG) presents with optic nerve damage at statistically normal IOPs (below 21 mmHg), suggesting vascular and neuroprotective factors beyond pressure also contribute to disease. This is where some supplement interest is most mechanistically relevant.

Medication and surgery are first-line — this cannot be overstated

Before discussing supplements, the critical point: stopping or reducing glaucoma medications based on supplement use is dangerous. The timeline of glaucoma progression is measured in years, and optic nerve damage from IOP spikes is irreversible. Any perceived effect of a supplement on IOP requires verification through tonometry by an eye care provider. No supplement has been validated as equivalent to first-line IOP-lowering medications.

Ginkgo biloba: optic nerve blood flow and neuroprotection

Ginkgo biloba has the most studied relationship with glaucoma among supplements, particularly for normal-tension glaucoma where vascular insufficiency may play a larger role than in pressure-driven disease.

Ginkgo's proposed mechanisms include:

• Vasoactive effects: Flavonoids and terpenoids in standardized extract improve blood flow by inhibiting platelet-activating factor and modulating nitric oxide
• Antioxidant protection: Reduces reactive oxygen species that contribute to retinal ganglion cell death
• Neuroprotection: May upregulate protective gene expression in retinal neurons

A 2003 small RCT by Quaranta et al. found that patients with NTG taking 160mg/day standardized ginkgo extract (EGb 761) for 4 weeks showed improved automated visual field performance compared to placebo. A follow-up study showed the benefit persisted with continued use. However, these studies are small and have not been replicated at scale.

Evidence grade: weak to moderate for NTG; insufficient for pressure-related glaucoma.

Caution: Ginkgo inhibits platelet-activating factor and may increase bleeding risk, particularly if combined with anticoagulants (warfarin, aspirin, clopidogrel). Discuss with your ophthalmologist and primary care provider before use.

Omega-3 fatty acids and IOP

Several small studies have suggested omega-3 supplementation may have modest IOP-lowering effects. A 2013 randomized crossover study found that participants taking 4g/day EPA+DHA for 3 months had a statistically significant reduction in IOP compared to baseline, though the absolute reduction was modest (approximately 2 mmHg).

The proposed mechanism involves omega-3 metabolites modulating aqueous humor dynamics. The evidence base is insufficient to recommend omega-3 as a primary IOP treatment, but given its favorable safety profile and cardiovascular benefits, it is a reasonable consideration as an adjunct.

Vitamin B3/niacinamide for neuroprotection

Niacinamide (nicotinamide), the amide form of vitamin B3, has emerged as a potentially interesting neuroprotective supplement for glaucoma based on preclinical data and one small clinical trial.

The mechanism: niacinamide is a precursor to NAD+, which is essential for mitochondrial energy production in retinal ganglion cells. Glaucomatous optic neuropathy involves progressive retinal ganglion cell death partly driven by mitochondrial dysfunction and energy failure. Boosting NAD+ availability may improve ganglion cell resilience.

A 2020 randomized trial (Williams et al.) found that 3g/day niacinamide combined with pyruvate improved visual field sensitivity compared to placebo in glaucoma patients whose IOP was already controlled. This is a promising early finding requiring larger replication.

Magnesium

Magnesium has been investigated for glaucoma primarily through its vasodilatory effects on blood vessels supplying the optic nerve. A small 1995 study found that magnesium supplementation (300mg/day) improved peripheral visual fields in glaucoma patients with cold-hand vasospasm (a marker of vascular instability). This effect was modest and has not been consistently replicated.

Antioxidants for optic nerve support

The retinal ganglion cells that constitute the optic nerve are among the most metabolically active cells in the body and highly vulnerable to oxidative stress. Antioxidants including vitamin C, vitamin E, lutein, and zeaxanthin are sometimes recommended as broadly supportive for retinal health, though none have demonstrated specific IOP-lowering effects or clear outcomes in glaucoma RCTs.

Monitoring with tonometry

If you are using any supplement with claimed IOP effects, the only way to verify whether your IOP is controlled is through regular tonometry — typically performed at your ophthalmology visits. Self-reported symptom improvement is not a reliable indicator of IOP status; glaucoma is often asymptomatic until advanced.

What to discuss with your ophthalmologist

Any supplement use in the context of glaucoma management should be disclosed to your ophthalmologist. Relevant considerations:

• Ginkgo and any blood-thinning medications or planned surgery
• High-dose niacinamide and liver function if used long-term
• Whether IOP is adequately controlled on current medications before adding adjunctive supplements

The bottom line

Supplements cannot replace IOP-lowering medications or surgery in glaucoma. Ginkgo biloba (160mg/day) has the most evidence for optic nerve support in normal-tension glaucoma; niacinamide (3g/day) is a promising neuroprotective adjunct; omega-3 may offer modest IOP reduction. All must be used under ophthalmologic supervision.

---

If you have glaucoma and want to organize your eye health supplement plan around the current evidence, Use Optimize free.

Related Articles

• Supplements for Glaucoma: Ginkgo, Omega-3, and Pressure Support